Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
HIV protease inhibitors (PIs) are a class of antiretroviral drugs used to inhibit viral
replication. They do so by interfering with a key step in the replication process. Some HIV
PIs have been associated with an increased risk of adverse cardiovascular side effects.
Further study is needed, however, to assess the full extent of effect of newer HIV PIs,
including atazanavir and lopinavir/ritonavir, on cardiovascular disease risk. This study will
compare the effects of atazanavir, lopinavir/ritonavir, and placebo on certain cardiovascular
disease risk factors in healthy people without HIV.
Phase:
N/A
Details
Lead Sponsor:
Indiana University National Heart, Lung, and Blood Institute (NHLBI)
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Atazanavir Sulfate HIV Protease Inhibitors Lopinavir Protease Inhibitors Ritonavir